| Abbott India's quarterly profit climbs 28% on strong demand |
Drugmaker Abbott India reported a 28% rise in fourth-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications. |
reuters.com |
2025-05-15 14:12:39 |
Czytaj oryginał (ang.) |
| Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes |
New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose monitors.1 Results also show a reduction in hospitalization for cardiovascular complications in adults with Type 2 diabetes on insulin using Libre technology.2 ABBOTT PARK, Ill., May 15, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from its REFLECT real-world studies that show the use of FreeStyle Libre® continuous glucose monitoring (CGM) technology is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes. |
prnewswire.com |
2025-05-15 13:05:00 |
Czytaj oryginał (ang.) |
| Abbott Outpaces Peers Defying Tariff Woes: Is ABT Stock a Smart Buy? |
Despite trade policy challenges, Abbott's global footprint and 90 manufacturing sites offer flexibility to manage regional risks and reroute supply chains. |
zacks.com |
2025-05-07 20:00:47 |
Czytaj oryginał (ang.) |
| Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It |
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2025-05-07 14:00:54 |
Czytaj oryginał (ang.) |
| MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know |
Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure. |
zacks.com |
2025-05-05 20:00:40 |
Czytaj oryginał (ang.) |
| Abbott Labs CEO on federal health care spending, investing in healthy people and weight loss drugs |
Robert Ford, Abbott Labs CEO, joins 'Power Lunch' to discuss government spending on health care and technological investments. |
youtube.com |
2025-05-05 19:10:32 |
Czytaj oryginał (ang.) |
| 2 Stocks, 2 Decades, $200. Is This the Long-Term Dividend Play for Your Portfolio? |
Investing in excellent dividend stocks can be a great strategy to mitigate risk and boost long-term returns. Companies that can dispense regular payouts to their shareholders -- especially those that have done so for a long time -- generally have stable and steadily growing businesses that can perform relatively well even amid downturns. |
fool.com |
2025-05-03 12:20:00 |
Czytaj oryginał (ang.) |
| US judge allows testimony that Abbott and Mead Johnson preterm baby formula caused deadly disease |
A federal judge on Friday said she will allow expert testimony that formula made by Abbott Laboratories and Reckitt Benckiser subsidiary Mead Johnson for premature babies can cause a fatal intestinal illness, as the companies face hundreds of lawsuits over the claims. |
reuters.com |
2025-05-02 21:59:41 |
Czytaj oryginał (ang.) |
| MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races |
The test, run on Abbott's portable i-STAT ® Alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concussion, producing lab-quality results in 15 minutes The test will be used by healthcare professionals in the medical facilities at all MotoAmerica races in 2025 ABBOTT PARK, Ill., and IRVINE, Calif. |
prnewswire.com |
2025-05-01 13:00:00 |
Czytaj oryginał (ang.) |
| Best Dividend Aristocrats For May 2025 |
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Edison (+25.65%), Cardinal Health (+17.82%), and Coca-Cola (+16.18%). 33 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.33%. |
seekingalpha.com |
2025-04-30 00:07:22 |
Czytaj oryginał (ang.) |
| Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information |
Collaboration brings together FreeStyle Libre® Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data for healthcare organizations Integration empowers U.S. clinicians to enhance patient care by incorporating Libre's data directly into their workflows ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology1, today announced that it has entered a first-of-its-kind agreement to integrate data from its world-leading1 Libre CGM systems directly into Epic's electronic health record systems in the U.S. The collaboration aims to improve workflow efficiency for providers through Epic's Aura software, which brings health systems together with diagnostics labs and medical device manufacturers. |
prnewswire.com |
2025-04-29 13:05:00 |
Czytaj oryginał (ang.) |
| PBH or ABT: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-04-28 16:45:25 |
Czytaj oryginał (ang.) |
| 3 Dividend Stocks to Buy and Hold for the Next Decade |
Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups. |
fool.com |
2025-04-28 11:47:00 |
Czytaj oryginał (ang.) |
| Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology |
Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has also begun in the ASCEND CSP pivotal clinical trial to evaluate Abbott's investigational CSP Implantable Cardioverter-Defibrillator (ICD) lead Conduction System Pacing is an evolving technique specifically designed to deliver pacing to the left bundle branch area of the heart to restore its natural electrical rhythm SAN DIEGO , April 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) acute clinical feasibility study, which demonstrated the safety and performance of the investigational AVEIR CSP leadless pacemaker technology. The AVEIR CSP acute clinical feasibility study is the world's first assessment of a leadless pacemaker delivering conduction pacing to the heart's left bundle branch (LBB) area. |
prnewswire.com |
2025-04-27 18:15:00 |
Czytaj oryginał (ang.) |
| New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib |
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE Mark Study confirm the long-term safety and efficacy of the Volt PFA System The data were presented at the 2025 Heart Rhythm Society (HRS) annual meeting ABBOTT PARK, Ill., April 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System for the treatment of atrial fibrillation (AFib). |
prnewswire.com |
2025-04-26 23:15:00 |
Czytaj oryginał (ang.) |
| Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock? |
With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025. |
zacks.com |
2025-04-25 20:00:51 |
Czytaj oryginał (ang.) |
| EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes |
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. |
zacks.com |
2025-04-24 16:40:42 |
Czytaj oryginał (ang.) |
| Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know |
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2025-04-23 14:00:58 |
Czytaj oryginał (ang.) |
| 2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market |
The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising Dividend Kings identified in March showed relative outperformance, averaging -3.15% vs. -8.16% for SPY. |
seekingalpha.com |
2025-04-23 13:58:08 |
Czytaj oryginał (ang.) |
| Abbott Labs' Rally Is Well Deserved - Fade The Rally For Now |
ABT continues to offer a compelling high-growth investment thesis, driven by the GLP-1 tailwinds on its Continuous Glucose Monitoring and adult nutrition offerings. This is significantly aided by the management's ability to reiterate its ambitious FY2025 guidance, despite the supposed hundreds of millions in tariff impact. Combined with the richer Free Cash Flow generation, healthier balance sheet, and high single-digits dividend per share growth, we believe that ABT remains well positioned to outperform ahead. |
seekingalpha.com |
2025-04-19 13:54:00 |
Czytaj oryginał (ang.) |
| My Best Dividend Aristocrats For March 2025 |
The ProShares S&P 500 Dividend Aristocrat ETF kicks off 2025 on a bright note with a gain of 2.81% in January. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 43 months of tracking these strategies, one strategy is generating a CAGR superior to NOBL. |
seekingalpha.com |
2025-02-27 17:59:55 |
Czytaj oryginał (ang.) |
| Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic? |
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? |
zacks.com |
2025-02-27 12:30:52 |
Czytaj oryginał (ang.) |
| 2025 Dividend Kings - Off To A Strong Start |
The Dividend Kings are outperforming the S&P 500 in 2025, up 4% YTD versus 1.39% for SPY. Ten Dividend Kings have already achieved double-digit returns, led by National Fuel Gas (+22.08%) and Abbott Laboratories (+20.71%). 2025 Dividend growth is looking promising, with ABM Industries and Walmart leading with 17.78% and 15.69% increases, respectively. |
seekingalpha.com |
2025-02-26 21:07:01 |
Czytaj oryginał (ang.) |
| Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It |
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2025-02-25 12:01:35 |
Czytaj oryginał (ang.) |
| Abbott Declares 405th Consecutive Quarterly Dividend |
ABBOTT PARK, Ill., Feb. 21, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share. |
prnewswire.com |
2025-02-21 12:48:00 |
Czytaj oryginał (ang.) |
| Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know |
The latest trading day saw Abbott (ABT) settling at $133.17, representing a +0.79% change from its previous close. |
zacks.com |
2025-02-20 21:01:29 |
Czytaj oryginał (ang.) |
| Expanding Diabetes Business Supports ABT Stock, FX Issues Stay |
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. |
zacks.com |
2025-02-19 12:45:38 |
Czytaj oryginał (ang.) |
| AHCO or ABT: Which Is the Better Value Stock Right Now? |
Investors looking for stocks in the Medical - Products sector might want to consider either AdaptHealth Corp. (AHCO) or Abbott (ABT). But which of these two stocks is more attractive to value investors? |
zacks.com |
2025-02-13 14:46:35 |
Czytaj oryginał (ang.) |
| Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™. |
DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg |
https://www.prnewswire.com |
2025-02-13 12:05:00 |
Czytaj oryginał (ang.) |
| Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever. |
Most companies don't survive for decades, much less pay regular dividends for that long. However, some rare corporations can pull it off. |
fool.com |
2025-02-13 08:35:00 |
Czytaj oryginał (ang.) |
| ABT Stock Jumps 12% Since Q4 Earnings: Time to Invest in Abbott? |
Abbott projects organic sales growth between 7.5% and 8.5% for 2025. |
zacks.com |
2025-02-12 14:55:19 |
Czytaj oryginał (ang.) |
| Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know |
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2025-02-11 12:01:14 |
Czytaj oryginał (ang.) |
| 3 No-Brainer Healthcare Stocks to Buy With $200 Right Now |
Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road. |
fool.com |
2025-02-10 06:20:00 |
Czytaj oryginał (ang.) |
| Why We Chose Abbott Labs Stock Amid Tariff And DeepSeek Volatility |
The last few weekends have been roiled by headlines. Here's why we took a different direction on this medical stock this week. |
investors.com |
2025-02-07 18:56:27 |
Czytaj oryginał (ang.) |
| Here are the best performing dividend aristocrats stocks in 2025 |
Dividend aristocrat stocks have largely done well in the past few years. The closely-followed ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has jumped by over 133% from its lowest level in 2020. |
invezz.com |
2025-02-06 01:03:00 |
Czytaj oryginał (ang.) |
| Abbott's 'Above the Bias' Film Reveals Misconceptions Can Impact Diabetes Care |
New survey shows 40% of people living with diabetes have skipped or missed a doctor's appointment due to shame or stigma1 70% of people with diabetes said supportive comments from others can significantly boost their motivation to manage their condition1 Abbott launches film that highlights challenges of living life with diabetes ABBOTT PARK, Ill., Feb. 4, 2025 /PRNewswire/ -- 'One cupcake won't kill you,' 'I'm going to get diabetes just looking at that,' 'That person doesn't look like they have diabetes. |
prnewswire.com |
2025-02-04 13:27:00 |
Czytaj oryginał (ang.) |
| 2 Unstoppable Dividend Stocks That Will Pay You for Life |
In the past few years, some high-profile dividend stocks have reduced their payouts, much to the chagrin of investors. As most income seekers want to avoid this fate, they might consider turning to arguably the most elite group of dividend payers on the market: Dividend Kings. |
fool.com |
2025-02-03 09:45:00 |
Czytaj oryginał (ang.) |
| My Best Dividend Aristocrats For February 2025 |
The ProShares S&P 500 Dividend Aristocrat ETF posted its 3rd worst monthly return in December, falling by 7.69%. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 42 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL. |
seekingalpha.com |
2025-01-29 05:11:07 |
Czytaj oryginał (ang.) |
| Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock |
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-01-28 12:00:34 |
Czytaj oryginał (ang.) |
| Reasons to Retain ABT Stock in Your Portfolio Now |
Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning. |
zacks.com |
2025-01-28 09:21:29 |
Czytaj oryginał (ang.) |
| HAE vs. ABT: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2025-01-03 14:51:09 |
Czytaj oryginał (ang.) |
| Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz |
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year |
youtube.com |
2025-01-03 14:06:01 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year? |
Here is how Abbott (ABT) and Acurx Pharmaceuticals, Inc. (ACXP) have performed compared to their sector so far this year. |
zacks.com |
2025-01-03 12:46:07 |
Czytaj oryginał (ang.) |
| Abbott Hosts Conference Call for Fourth-Quarter Earnings |
ABBOTT PARK, Ill., Jan. 2, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2024 financial results on Wednesday, Jan. 22, before the market opens. |
prnewswire.com |
2025-01-02 11:00:00 |
Czytaj oryginał (ang.) |
| 3 Dividend Growth Beasts That Have Raised Their Payouts for a Combined 165 Years |
Want some solid dividend growth stocks with incredible track records of increasing their payouts? Here's a list of stocks that have been raising their dividend payments consistently for more than 50 consecutive years. |
fool.com |
2025-01-02 10:00:00 |
Czytaj oryginał (ang.) |
| Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It |
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-01-01 12:01:17 |
Czytaj oryginał (ang.) |
| 5 MedTech Stocks That Are Poised to Beat the Market in 2025 |
Here, we discuss five stocks that are likely to generate better than the market, driven by strong demand for existing products and the addition of innovative new devices. |
zacks.com |
2024-12-30 12:01:38 |
Czytaj oryginał (ang.) |
| My New Year's Resolution For 2025: Invest $10,000 In These 6 Stocks |
I review here the stocks of six quality companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends. Dividend growth investing is not a get-rich-quick strategy, it requires commitment and a long-term mindset. Making a New Year's resolution is a great way to help maintain that mindset. I discuss two scenarios of hypothetical investors who start their journey in 2025. I detail the significant impact a long-term commitment – even without additional investments – can make. |
seekingalpha.com |
2024-12-30 12:00:38 |
Czytaj oryginał (ang.) |
| Highest Quality Dividend Kings For 2025 |
Only 11 Dividend Kings outperformed the S&P 500 during the last decade based on Total Return. 5 Dividend Kings earn the rank of "High Quality" based on my custom quantitative model. Using a variation of a truncated custom quality score could have generated a total return nearly double that of the S&P 500 during the last 9 years. |
seekingalpha.com |
2024-12-30 09:30:00 |
Czytaj oryginał (ang.) |
| 2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now |
A few different elements can make a stock a no-brainer buy. The company could be the leader in its market, or well diversified across various markets. |
fool.com |
2024-12-28 06:15:00 |
Czytaj oryginał (ang.) |
| Growing Biosimilars Business, New Partnerships Support ABT Stock |
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. |
zacks.com |
2024-12-27 11:51:25 |
Czytaj oryginał (ang.) |
| Is Abbott Stock Worth Buying at a Discounted P/S Valuation? |
Abbott's strong market position, promising growth prospects and consistent share gains make it a compelling pick for investors. |
zacks.com |
2024-12-26 14:01:09 |
Czytaj oryginał (ang.) |
| Abbott (ABT) Ascends But Remains Behind Market: Some Facts to Note |
Abbott (ABT) closed the most recent trading day at $114.76, moving +0.39% from the previous trading session. |
zacks.com |
2024-12-24 20:51:15 |
Czytaj oryginał (ang.) |
| Abbott (ABT) Rises Yet Lags Behind Market: Some Facts Worth Knowing |
The latest trading day saw Abbott (ABT) settling at $114.31, representing a +0.07% change from its previous close. |
zacks.com |
2024-12-23 21:05:48 |
Czytaj oryginał (ang.) |
| Abbott and DexCom settle glucose monitor patent disputes |
Abbott Laboratories said on Monday it and DexCom have reached an agreement to settle all patent disputes between the companies related to continuous glucose monitoring devices. |
reuters.com |
2024-12-23 18:17:36 |
Czytaj oryginał (ang.) |
| Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline |
Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline |
seekingalpha.com |
2024-12-21 06:27:28 |
Czytaj oryginał (ang.) |
| My Top 10 Stocks to Buy for 2025 |
It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too. |
fool.com |
2024-12-21 06:05:00 |
Czytaj oryginał (ang.) |
| 4 Healthcare Technology Innovators to Invest in Before the New Year |
Here, we have presented four healthcare technology stocks for stable portfolio gains in 2025: VCYT, OMCL, MASI and ABT. |
zacks.com |
2024-12-19 14:00:40 |
Czytaj oryginał (ang.) |
| Reasons to Retain ABT Stock in Your Portfolio Now |
Investors feel optimistic about Abbott's robust strength in the EPD and Nutrition businesses. Yet, unfavorable forex impacts are concerning. |
zacks.com |
2024-12-19 11:15:26 |
Czytaj oryginał (ang.) |
| 2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond |
What will be the hottest investing trend on Wall Street next year? Maybe artificial intelligence will keep up its momentum, or perhaps interest in weight loss-focused pharmaceutical companies will increase. |
fool.com |
2024-12-19 08:00:00 |
Czytaj oryginał (ang.) |